ReviewEuropean journal of heart failure2021
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations.
Review in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.ESC heart failure · 2025Pooled it
- Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort.European journal of heart failure · 2022Trial
- Revisiting thoracic splanchnic nerve anatomy: implications for thoracoscopic splanchnicectomy and pain management.Surgical and radiologic anatomy : SRA · 2026Article
- Device-driven cyclic compression of the superior vena cava as a preload reduction strategy to improve cardiac function in heart failure: a pilot feasibility study.Scientific reports · 2026Article
- Greater Splanchnic Nerve Ablation in Heart Failure with Preserved Ejection Fraction: a Mini-Narrative Review of Emerging Evidence.European journal of medical research · 2025Review
- Simulated microgravity exposure markedly attenuates the baroreflex total loop gain and induces orthostatic hypotension in male rats.Physiological reports · 2025Article
- Remote Dielectric Sensing Technology in Heart Failure: Correlating Lung-Fluid Volume Shifts with Postural Changes and Dyspnea Severity.CJC open · 2025Article
- Hypoxic responsiveness and gut fermentation capacity in heart failure patients: preliminary results.Frontiers in physiology · 2025Article
- Cardio-Renal Syndrome: Latest Developments in Device-Based Therapy.Journal of clinical medicine · 2024Review
- Heart Failure: a Punch from the Gut.Current heart failure reports · 2024Review
- Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2024Article
- Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials.ESC heart failure · 2024Review
- The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF.Journal of clinical medicine · 2023Review
- Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction.The journal of physiological sciences : JPS · 2023Article
- Advances in novel devices for the treatment of heart failure.Heart failure reviews · 2023Review
- Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2023Review
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives.Pharmaceutics · 2022Review
- Review
- Novel Therapeutic Devices in Heart Failure.Journal of clinical medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Volume recruitment from the splanchnic compartment is an important physiological response to stressors such as physical activity and blood loss. In the setting of heart failure (HF), excess fluid redistribution from this compartment leads to increased cardiac filling pressures with limitation in exercise capacity. Recent evidence suggests that blocking neural activity of the greater splanchnic nerve (GSN) could have significant benefits in some patients with HF by reducing cardiac filling pressures and improving exercise capacity. However, to date the long-term safety of splanchnic nerve modulation (SNM) in the setting of HF is unknown. SNM is currently used in clinical practice to alleviate some forms of chronic abdominal pain. A systematic review of the series where permanent SNM was used as a treatment for chronic abdominal pain indicates that permanent SNM is well tolerated, with side-effects limited to transient diarrhoea or abdominal colic and transient hypotension. The pathophysiological role of the GSN in volume redistribution, the encouraging findings of acute and chronic pilot SNM studies and the safety profile from permanent SNM for pain provides a strong basis for continued efforts to study this therapeutic target in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.